# NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
Canonical URL: https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-september-5b6d744a
Ticker: NAMS
Company: NewAmsterdam Pharma
Source: NewAmsterdam Pharma
Published: 2026-09-02 12:00 EST
Original Source URL: https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-participate-upcoming-investor-conferences-8
## Summary

NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”)

## Article Body
NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Wednesday, September 9, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 3:45 p.m. ET on Wednesday, September 9.

Cantor Global Healthcare Conference 2026 in New York, NY on Thursday, September 10, 2026. Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 2:45 p.m. ET on Thursday, September 10.

Live webcasts of both presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com . Following the live webcasts, archived replays will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact

Matthew Philippe P: 1-917-882-7512 [email protected]

Media Contact

Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 [email protected]

Investor Contact

Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected]
## Recent Company News
- 2026-09-03 20:01 EST — [NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-c0300178) — Source: NewAmsterdam Pharma
- 2026-09-02 12:00 EST — [NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-september-5b6d744a) — Source: NewAmsterdam Pharma
- 2026-08-26 12:00 EST — [NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-announces-upcoming-presentations-at-the-european-society-of--729c25ac) — Source: NewAmsterdam Pharma
- 2026-08-06 20:01 EST — [NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-39377bb8) — Source: NewAmsterdam Pharma
- 2026-08-05 11:00 EST — [NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-provides-corporate-update-and-reports-second-quarter-financi-71d32549) — Source: NewAmsterdam Pharma
## Related News
- 2026-09-06 05:00 EST — ROIV — [Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call](https://biopharmsignal.com/news/ROIV/roivant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat--bf1ea553)
- 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd)
- 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f)
- 2026-09-04 20:05 EST — LIXT — [NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS](https://biopharmsignal.com/news/LIXT/nomad-power-solutions-announces-adjournment-of-special-meeting-of-stockholders-74cd9e2e)
- 2026-09-04 20:05 EST — AVTX — [Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-lis-cc7baaf2)